DexCom is trading 4% down at $73.28 as a recent rebound stalled and healthcare stocks sell off following HCA Healthcare’s profit warning.
- The move follows a broader sector decline triggered by HCA Healthcare's disappointing outlook, which has dampened investor appetite for medical technology stocks.
- Sentiment remains pressured by long-term concerns over 2026 growth targets, increasing competition, and reliability issues surrounding the G7 device.